Clinuvel Pharmaceuticals (ASX:CUV) Cash Conversion Cycle : 1,185.83 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Clinuvel Pharmaceuticals's Days Sales Outstanding for the six months ended in Dec. 2023 was 95.85.
Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2023 was 1879.39.
Clinuvel Pharmaceuticals's Days Payable for the six months ended in Dec. 2023 was 789.41.
Therefore, Clinuvel Pharmaceuticals's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 1,185.83.

Clinuvel Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Cash Conversion Cycle Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash Conversion Cycle

Get a 7-Day Free Trial

73.64

66.02

112.17

130.46

257.88

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash Conversion Cycle	Get a 7-Day Free Trial															101.52	71.36	165.01	151.10	1,185.83

Competitive Comparison of Clinuvel Pharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Cash Conversion Cycle falls into.

Clinuvel Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Clinuvel Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Jun. 2023 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	85.53	+	235.7	-	63.35
	=	257.88

Clinuvel Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	95.85	+	1879.39	-	789.41
	=	1,185.83

Clinuvel Pharmaceuticals (ASX:CUV) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Clinuvel Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines